Transcription factor-based drug design in anticancer drug development

Molecular Medicine

Volumn 3, Issue 12, 1997, Pages 799-810

  Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HELIX LOOP HELIX PROTEIN; LEUCINE ZIPPER PROTEIN; RNA POLYMERASE II; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CELL GROWTH; COMPUTER MODEL; DRUG DESIGN; DRUG STRUCTURE; MOLECULAR MODEL; ONCOGENE MYC; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

EID: 0031415709     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401717     Document Type: Review

References (48)

1. Latchman DS. (1995) Eukaryotic Transcription Factors, 2nd ed. Academic Press, London.
2. Tjian R. (1996) The biochemistry of transcription in eukaryotes: a paradigm for multisubunit regulatory complexes. Phil. Trans. R. Soc. Lond. B 351: 491-499.
3. Harrison SC. (1991) A structural taxonomy of DNA-binding domains. Nature 353: 715-719.
4. Papavassiliou AG. (1995) Transcription factors. N. Engl. J. Med. 332: 45-47.
5. Papavassiliou AG. (1995) Transcription factors: structure, function, and implication in malignant growth. Anticancer Res. 15: 891-894.
6. Travers A. (1993) DNA-protein interactions: sequence specific recognition. In: DNA-Protein Interactions. Chapman & Hall, London, pp. 52-86.
7. Pabo CO, Sauer RT. (1992) Transcription factors: Structural families and principles of DNA recognition. Annu. Rev. Biochem. 61: 1053-1095.
8. Ouzounis CA, Papavassiliou AG. (1997) DNA-binding motifs of eukaryotic transcription factors. In: Papavassiliou AG (ed). Transcription Factors in Eukaryotes. Molecular Biology Intelligence Unit. Landes Bioscience, Austin & Springer-Verlag, Heidelberg, pp. 1-21.
9. Tjian R, Maniatis T. (1994) Transcriptional activation: A complex puzzle with few easy pieces. Cell 77: 5-8.
10. Edwards DR. (1994) Cell signalling and the control of gene transcription. Trends Pharmacol. Sci. 15: 239-244.
11. Hunter T, Karin M. (1992) The regulation of transcription by phosphorylation. Cell 70: 375-387.
12. Karin M. (1994) Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr. Opin. Cell Biol. 6: 415-424.
13. Calkhoven CF, AB G. (1996) Multiple steps in the regulation of transcription-factor level and activity. Biochem. J. 317: 329-342.
14. Bishop JM, Hanafusa H. (1996) Proto-oncogenes in normal and neoplastic cells. In: Bishop JM, Weinberg RA (eds). Molecular Oncology. Scientific American, New York, pp. 61-83.
15. Macdonald F, Ford CHJ. (1997) Molecular Biology of Cancer. BIOS Scientific, Oxford, pp. 13-72.
16. Forrest D, Curran T. (1992) Crossed signals: oncogenic transcription factors. Curr. Opin. Genet. Dev. 2: 19-27.
17. Cooper GM. (1995) Transcription factors. In: Oncogenes, 2nd ed. Jones & Bartlett, Boston, pp. 255-278.
18. Wisdom RM. (1997) Oncogenic transcription factors. In: Papavassiliou AG (ed). Transcription Factors in Eukaryotes. Molecular Biology Intelligence Unit. Landes Bioscience, Austin & Springer-Verlag, Heidelberg, pp. 219-234.
19. Pawson T. (1996) The biochemical mechanisms of oncogene action. In: Bishop JM, Weinberg RA (eds). Molecular Oncology. Scientific American, New York, pp. 85-109.
20. Rabbitts TH. (1994) Chromosomal translocations in human cancer. Nature 372: 143-149.
21. Latchman DS. (1996) Transcription-factor mutations and disease. N. Engl. J. Med. 334: 28-33.
22. Sawyers CL, Denny CT. (1994) Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 77: 171-173.
23. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM. (1994) A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76: 333-343.
24. Fredericks WJ, Galili N, Mukhopadhyay S, et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15: 1522-1535.
25. Marcu KB, Bossone SA, Petel AJ. (1992) Myc function and regulation. Annu. Rev. Biochem. 61: 809-860.
26. Cooper GM. (1995) Oncogenes and chromosome translocation. In: Oncogenes, 2nd ed. Jones & Bartlett, Boston, pp. 99-112.
27. Knudson AG. (1993) Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A. 90: 10914-10921.
28. Davies RC, Hastie ND. (1997) Tumor suppression by 'transcription' factors. In: Papavassiliou AG (ed). Transcription Factors in Eukaryotes. Molecular Biology Intelligence Unit. Landes Bioscience, Austin & Springer-Verlag, Heidelberg, pp. 297-316.
29. Marx J. (1993) How p53 suppresses cell growth. Science 262: 1644-1645.
30. Hastie ND. (1993) Wilm's tumour gene and function. Curr. Opin. Genet. Dev. 3: 408-413.
31. Sarma MH. (1997) p73 gene: A new relative of p53. Cancer Watch 6: 139-140.
32. La Thangue NB. (1994) DP and E2F proteins: components of a heterodimeric transcription factor implicated in cell cycle control. Curr. Opin. Cell Biol. 6: 443-450.
33. Weinberg RA. (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
34. Cooper GM. (1995) Tumor suppressor genes in human neoplasms. In: Oncogenes, 2nd ed. Jones & Bartlett, Boston, pp. 145-161.
35. Marshall GR, Cramer RD III. (1988) Three-dimensional structure-activity relationships. Trends Pharmacol. Sci. 9: 285-289.
36. Peisach E, Casebier D, Gallion SL, et al. (1995) Interaction of a peptidomimetic aminimide inhibitor with elastase. Science 269: 66-69.
37. Neidle S. (1994) Discovery of new anticancer drugs by computer-aided drug design. Ann. Oncol. 5(Suppl. 4): S51-S54.
38. Maulik S, Patel SD. (1997) Protein engineering and computer-assisted drug design. In: Molecular Biotechnology - Therapeutic Applications and Strategies. Wiley-Liss, New York, pp. 109-153.
39. Brint AT, Willett PJ. (1987) Upperbound procedures for the identification of similar three-dimensional chemical structures. J. Comput. Aided Mol. Des. 2: 311-320.
40. Wang H. (1991) Grid-search molecular accessible surface algorithm for solving the protein-docking problem. J. Comput. Chem. 12: 746-750.
41. Goodford PJ. (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28: 849-857.
42. Smellie AS, Crippen GM, Richards WG. (1991) Fast drug-receptor mapping by site-directed distances: A novel method of predicting new pharmacological leads. J. Chem. Inf. Comput. Sci. 31: 386-392.
43. Kuntz ID. (1992) Structure-based strategies for drug design and discovery. Science 257: 1078-1082.
44. Sudarsanam S, Virca GD, March CJ, Srinivasan S. (1992) An approach to computer-aided inhibitor design: Application to cathepsin L. J. Comput. Aided Mol. Des. 6: 223-233.
45. Desjarlais RL, Sheridan RP, Seibel GL, Dixon JS, Kuntz ID, Venkataraghavan R. (1988) Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J. Med. Chem. 31: 722-729.
46. Lawrence MC, Davis PC. (1992) CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure. Proteins 12: 31-41.
47. Rotstein SH, Murcko MA. (1993) GenStar: A method for de novo drug design. J. Comput. Aided Mol. Des. 7: 23-43.
48. Peterson MG, Baichwal VR. (1993) Transcription factor based therapeutics: drugs of the future? Trends Biotechnol. 11: 11-18.